To date, this is the only product that MXC has come up with that actually works. Why has it taken 5 years to get to this point - and why has MXC not pushed this product harder and faster.
Highlights • CannEpil®, MGC Pharma’s Investigational Medicinal Product (“IMP”) has now been successfully imported and received by its first patients in the United Kingdom. • The first UK patient has received CannEpil® through the ‘I AM Billy Foundation’, supporting the RESCAS study. • Additionally, the Company has delivered CannEpil® to its first patient in the UK via the Named Patient Request programme. • This follows the announcement on 11 April 2023 that CannEpil® was now available in the United Kingdom via Named Patient Request, and available to be prescribed by doctors on The General Medical Council (“GMC”) specialist register across the UK. • CannEpil® is in the process of a clinical development programme for patients suffering from refractory (or drug-resistant) epilepsy.
MXC Price at posting:
0.6¢ Sentiment: None Disclosure: Not Held
